Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
Trial Details
- NCT ID
- NCT07645651
- Phase
- PHASE1
- Sponsor
- University of Washington
- Status
- RECRUITING
- Cancer Type
- Pancreatic Cancer
- Interventions
- Samuraciclib
- Computed Tomography
- Endoscopic Ultrasound Biopsy
- Biospecimen Collection
- Locations (sample)
- Seattle, Washington, United States|47.60621,-122.33207
Key Eligibility Criteria
- Histologically or cytologically proven basal pancreatic adenocarcinoma. Histologies other than adenocarcinoma, or any mixed histologies, will NOT b…
- Basal tumors are defined as GATA6- and HMGA2+. Tumor cores are considered positive for GATA6 or HMGA2 if greater than 10% of tumor epithelial cells…
- Resectable, borderline resectable, or locally advanced pancreatic ductal adenocarcinoma (PDA) at diagnosis based on contrast-enhanced CT or magneti…
- There must be no evidence of metastatic disease
For full eligibility, visit ClinicalTrials.gov.